Merck & Co.
AWARDS
NEWS
As the biotech world awaits the announcement of Merck’s anticipated buyout of Seagen, an arbitrator came down on the side of Daiichi Sankyo in a patent battle against the Seattle-based biotech.
Daiichi Sankyo and AstraZeneca report another first-in-class approval for Enhertu, Bayer snags an sNDA in metastatic hormone-sensitive prostate cancer and Merck faces contamination challenges with Januvia.
The FDA will still allow continued distribution of sitagliptin containing NTTP with an acceptable intake limit of 37 ng per day and up to 246.7 ng per day.
Using Cerevance’s proprietary NNETSseq technology platform, Merck and Cerevance have partnered to identify new targets for the treatment of Alzheimer’s disease.
The real positive drivers were Eylea and Dupixent. Eylea climbed 14% to $1.62 billion, while Dupixent sales jumped almost 40% to $2.09 billion for the second quarter.
The debate over drug pricing tends to heat up during election season. With the mid-terms in November, we’re going through the cycle once again, sparked by provisions in the Inflation Reduction Act.
JOBS
IN THE PRESS